Genus Power Infrastructures receives consent to operate for new moulding plant in Rajasthan
Shares of Genus Power Infrastructures Ltd ended at ₹262.40, down by ₹0.40, or 0.15%, on the BSE.
Uncategorized
Abbott India to sell Novo Nordisk’s semaglutide, weight-loss drug behind Ozempic
Abbott India has partnered Novo Nordisk to market semaglutide under the Extensior brand, aiming to tap rising demand for advanced diabetes therapies in one of the world’s fastest-growing markets.
Brigade Enterprises launches ‘Brigade Stellaris’ in Chennai with ₹1,700 crore GDV
Shares of Brigade Enterprises Limited ended at ₹703.65, down by ₹12.25, or 1.71%, on the BSE.
Niva Bupa gets IRDAI show cause notice after inspection
Niva Bupa Health Insurance received a Show Cause Notice and Letter of Advice from IRDAI after a February 2025 inspection, confirming compliance steps and no current impact on operations.
Quality Power Electrical Equipments secures multiple HVDC reactor orders worth ₹34 crore
Shares of Quality Power Electrical Equipments Ltd ended at ₹868.15, down by ₹36.10, or 3.99%, on the BSE.
IIFL Home Finance Limited raises $300 million from Asian Development Bank to expand affordable housing for women
IIFL Home Finance secures a 300 million dollar loan from Asian Development Bank and partners to boost affordable, green housing finance for low-income women in India amid a major housing deficit.
GAIL board approves ₹1,736 crore wind power project in Maharashtra
Shares of GAIL ended today’s trade 0.6% lower at ₹168.85 on the NSE.
NCC gets interim relief as Telangana High Court suspends NHAI debarment order
Shares of NCC Ltd ended at ₹152.80, down by ₹0.60, or 0.39%, on the BSE.
What’s driving strong flows into gold and silver ETFs despite volatility, explains ICICI Pru AMC’s Haria
Chintan Haria of ICICI Prudential highlights strong gold and silver ETF flows amid price surges, global risks, central bank demand, and product design easing investor access and volatility management.
Aurobindo Pharma arm Eugia Pharma unit-I inspected by US FDA; 4 observations reported
Shares of Aurobindo Pharma Ltd ended at ₹1,220.70, down by ₹1.30, or 0.11%, on the BSE.